Pegylated liposomal doxorubicin combined with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory solid tumor: a single-arm, open-label, phase I study
-
Published:2024-07
Issue:
Volume:73
Page:102701
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Lu Suying,
Wang Juan,
Huang Junting,
Sun Feifei,
Zhu Jia,
Que Yi,
Li Hui,
Guo Ying,
Cai Ruiqing,
Zhen Zijun,
Sun Xiaofei,
Zhang YizhuoORCID
Reference30 articles.
1. Late cardiac effects of cancer treatment;Lenihan;J Clin Oncol,2012
2. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial;Lipshultz;Lancet Oncol,2010
3. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association;Lipshultz;Circulation,2013
4. Individual prediction of heart failure among childhood cancer survivors;Chow;J Clin Oncol,2015
5. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies;Wouters;Br J Haematol,2005